Phase 1/2 × OTHER × Lymphoma, Mantle-Cell × Clear all
NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

University of Chicago

Phase 1/2 Completed
55 enrolled 17 charts
NCT03842696 2026-01-27

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

University of Michigan Rogel Cancer Center

Phase 1/2 Active not recruiting
43 enrolled
NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Fred Hutchinson Cancer Center

Phase 1/2 Active not recruiting
53 enrolled 11 charts
NCT03622788 2025-12-17

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
16 enrolled
NCT01998035 2024-08-22

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
58 enrolled 11 charts
NCT00816413 2023-08-14

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

University of Nebraska

Phase 1/2 Withdrawn
NCT01805037 2021-09-01

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Northwestern University

Phase 1/2 Terminated
20 enrolled 17 charts
NCT01075321 2020-10-22

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
58 enrolled 12 charts